GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2026 to 2035
Starting on a lower dose helps your body build tolerance, especially to stomach-related side effects such as nausea, vomiting and diarrhoea
However, the changes in the gut microbiota were not completely consistent among these studies
Can I switch between semaglutide and tirzepatide if I'm not tolerating one
Heart health (Major Adverse Cardiovascular Events MACE) early evidence suggests a possible cardiovascular benefit, with a large dedicated outcomes trial underway to confirm this (JAMA Network Open, 2024)
